Treatment of metastatic non-small cell lung cancer

Current Opinion in Oncology

Volumn 8, Issue 2, 1996, Pages 120-125

  Van Zandwijk, Nico ^a   Giaccone, G ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EDATREXATE; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN C; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TENIPOSIDE; VINBLASTINE; VINDESINE;

ALOPECIA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; GASTROINTESTINAL TOXICITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 0029936052     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199603000-00008     Document Type: Review

References (48)

1. Mattheus MJ, Kanhawa S, Pickren J, Robinette D: Frequency of residual and metastatic disease in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep 1973, 4:63-67.
2. Travis WD, Travis LB, Devesa SS: Lung cancer. Cancer 1995, 75:191-202.
3. Slebos RJC, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJLM, Wagenaar SJSC, Vanderschueren RGJRA, Van Zandwijk N, Mooi WJ, Bos JL, Rodenhuis S: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990, 323:561-565.
4. Feld R, Rubinstein LV, Weisenberger TH, and the Lung Cancer Study Group: Sites of recurrence in resected stage I non-small cell lung cancer: a guide for future studies. J Clin Oncol 1984, 2:1352-1358.
5. O'Connell J, Kris MG, Gralla RJ, Groshen S, Trust A, Fiore SJ, Kelsen DP, Heelan RT, Golbey RB: Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986, 4:1604-1614.
6. Ruckdeschel JC, Finkelstein DH, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S: A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986, 4:14-22.
7. Bakowski MT, Crouch JD: Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer Treat Rev 1983, 10:159-172.
8. Joss RA, Cavalli F, Goldhirsh A, Mermillod B, Brunner KW: New agents in non-small cell lung cancer. Cancer Treat Rev 1984, 11:205-236.
9. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D: Phase II study of taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993, 85:388-394.
10. Murphy WK, Fossella FV, Winn RJ: Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993, 85:384-388.
11. Hainsworth JD, Thompson DS, Greco FA: Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995, 13:1609-1614.
12. Comis RL, Friedland DM: New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including from the Seventh World Conference on Lung Cancer. Lung Cancer 1995, 12(suppl2):S63-S99. A recent and well-documented overview of new agents in NSCLC.
13. Fossella FV, Jin Soo Lee JS, Berille J, Hong WK: Summary of phase II data of docetaxel (taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 1995, 22(suppl 4):22-29.
14. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hanssen HH: Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1994, 12:1821-1826.
15. Abratt R, Bezwoda W, Falkson G, Goedhals L, Hacking D, Rugg T: Efficacy and safety profile of gemcitabine in non-small cell lung cancer (NSCLC): a phase II study. J Clin Oncol 1994, 12:1535-1540.
16. Gatzemeier U, Shephard F, Le Chevalier T, Weynards P, Cottier B, Groen HJM, Rosso R, Mattson K, Cortes-Funes H, Tonato M, Voi M: A multicenter phase II trial with gemcitabine in non-small cell lung cancer (NSCLC) [abstract]. Lung Cancer 1994, 11(suppl 1):121.
17. Steward WP, Dunlop DJ, Cameron C, Dabouis G, Lacroix H, Talbot D, Walling J, Ponzio A, Kleisbauer JP, Thomas P, Guerin JC, Perol M, Samson C: Cisplatin + gemcitabine in non-small cell lung cancer (NSCLC): a phase I dose escalation study [abstract]. Lung Cancer 1994, 11(suppl 1):114.
18. Depierre A, Lemarie E, Dabouis G, Gamier G, Jacoulet P, Dalphin JC: A phase II study of navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991, 14:115-119.
19. Le Chevalier T, Brisgand D, Douillard JY, Puyol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomey P, Cigolaris S, Gottfried M, Ruffie P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994, 12:360-367. An important randomized comparison between vinorelbine alone and in combination with cisplatin against the standard cisplatin-vindesine combination.
20. Smith TJ, Hillner BE, Neighbors DM, McGorley PA, Le Chevalier T: Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small cell lung cancer. J Clin Oncol 1995, 9:2166-2173. Cost-effectiveness study revealing that chemotherapy is not extremely costly but is comparable in cost to other health care expenditures.
21. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T, for the CTP-11 Lung Cancer Study Group: A phase II study of CPT-11, a new derivative of camptothecin, for previous untreated non-small cell lung cancer. J Clin Oncol 1992, 10:16-20.
22. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Kishimoto S: CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol 1992, 10:1775-1780.
23. Pignon J, Stewart L, Souhami R, Arriagada R: A meta-analysis using individual patient data from randomised clinical trials of chemotherapy in non-small cell lung cancer: survival in the locally advanced setting [abstract]. Proc Am Soc Clin Oncol 1994, 13:334. A thorough meta-analysis of chemotherapy in NSCLC using the data from all traceable trials.
24. Albain KS, Crowley JJ, LeBlanc M, Livingston RB: Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991, 9:1618-1926.
25. Donnadieu N, Paesmans N, Sculier JP: Chemotherapy of non-small cell lung cancer according to disease extent: a meta-analysis of the literature. Lung Cancer 1991, 7:243-252.
26. Van Zandwijk N, Dalesio O: Platinum-based chemotherapy in non-small cell lung cancer: the experience of the EORTC. Semin Oncol 1994, 21(suppl 6):66-71.
27. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Glick J: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989, 7:1602-1613.
28. Waits TM, Johnson DJ, Hainsworth JD, Hande KR, Thomas M, Greco FA: Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial. J Clin Oncol 1992, 10:292-296.
29. Chang AY, Asbury RF, Boros L, Garrow GC, Hsieh S: Ifosfamide/carboplatin/etoposide chemotherapy in patients with metastatic non-small cell lung cancer. Semin Oncol 1995, 22(suppl 7):9-12.
30. Van Zandwijk N, Ten Bokkel Huinink WW, Wanders J, Simonetti G, Dubbelman R, Franklin H, Van Tinteren H, McVie JG: Dose finding studies with carboplatin, ifosfamide, etoposide, and mesna in non-small cell lung cancer. Semin Oncol 1990, 17:16-19.
31. Drings P: Ifosfamide in the Treatment of Bronchial Carcinoma. In Ifosfamide in Tumor Therapy. Edited by Brade WP, Nagel GA, Seeber S. Basel: Karger; 1987:294-318.
32. Perez EA, Gandara DR: Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer. Semin Oncol 1994, 21(suppl 4):2-5.
33. Ginsberg RJ, Kris MG, Armstrong JG: Cancer of the Lung. In Cancer: Principles & Practice of Oncology, edn 4. Edited by DeVita VT, Hellman S, Rosenberg SA. JB Lippincott; 1993:673-723.
34. Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR, Woodburn R, Drasga R, Songer J, Fisher W, Stephens D, Hui S: Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small cell lung cancer. J Clin Oncol 1986, 5:1037-1043.
35. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Glick J: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1989, 7:1602-1613.
36. Gralla RJ, Kris MG, Burke MT, Kelsen DP, Heelan R: The influence of the addition of mitomycin to vindesine plus cisplatin in a random-assignment trial in 120 patients with non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1986, 5:182.
37. Weick JK, Crowley J, Natale RB, Lin Hom B, Rivkin S, Coltman CA Jr, Taylor SA, Livingston RB: A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1991, 9:1157-1162.
38. Fukuoka M, Masuda N, Furuse K, Negoro S, Takada M, Matsui K, Takifuji N, Kudoh S, Kawahara M, Ogawara M, Kodama N, Kubota K, Yamamoto M, Kusunoki Y: A randomized trial in inoperable non-small cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol 1991, 9:606-613.
39. Hainsworth J, Johnson D, Hande K: Chemotherapy of advanced non-small cell lung cancer: a randomized trial of three cisplatin-based chemotherapy regimens. Am J Clin Oncol 1989, 12:345-349.
40. Kris MG, Gralla RJ, Wertheim MS, Kelsen DP, O'Connell JP, Burke MT, Fiore JJ, Cibas IR, Heelan RT: Trial of the combination of mitomycin, vindesine and cisplatin in patients with advanced non-small cell lung cancer. Cancer Treat Rev 1986, 70:1091-1096.
41. Cullen MH: The MIC regimen in non-small cell lung cancer. Lung Cancer 1993, 9(suppl 2):81-89.
42. Klastersky J: VP16 and cisplatin in the treatment of non-small cell lung cancer. Semin Oncol 1985, 12:17-20.
43. Crino L, Clerici M, Figoli F, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Constanzo F, Boni C, Corgua E, Darwish S, Scarcella L, Santucci A, Ballatori E, Tonato M: Chemotherapy of advanced non-small cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 1995, 6:347-353. Randomized comparison between cisplatin-etoposide and two popular three-drug regimens, revealing a better therapeutic index for the three-drug regimens.
44. Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough. J Clin Oncol 1993, 11:1866-1872.
45. Souquet PJ, Chauvin F, Boissel JP, Cellerine R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL, Bernard JP: Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993, 342:19-21.
46. Ellis PA, Smith IE, Hardy JR, Nicolson MC, Talbot DC, Ashley SE, Priest K: Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. Br J Cancer 1995, 71:366-370. One of the few studies in NSCLC with an important focus on the effect of chemotherapy on symptoms.
47. Hickish TF, Smith IE, Middleton G, Nicholson M: Patient preference for extended palliative chemotherapy for non-small cell lung cancer. Lancet 1993, 345:857-858.
48. Jaakkimainen L, Goodwin PJ, Ward P, Murray N, Rapp E: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell cancer. J Clin Oncol 1990, 8:1301-1309.